Doxorubicin

Global Market Trajectory & Analytics

MCP21662

EXECUTIVE ENGAGEMENTS

POOL

601
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

122
Interactions with Platform & by Email

PARTICIPANTS

24
Unique # Participated

VALIDATIONS

12
Responses Validated*

COMPANIES

59
Responses Validated*
* Login for a full stack data experience

DATE

MAY 2021

TABLES

126

PAGES

288

EDITION

8

PRICE

USD 5600

CODE

MCP21662


COMPETITIVE METRICS

COMPANY

D S N T

% *

Accord Healthcare Ltd.

Actiza Pharmaceutical Pvt., Ltd.

Angel Biogenics Private Limited

Avacta Group

B Joshi Agrochem Pharma

Baxter International, Inc.

Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd.

Biocompare

Biovencer Healthcare Private Limited

Boryung Co., Ltd.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Global Doxorubicin Market to Reach $1.3 Billion by 2026

Doxorubicin, a medical compound originally derived from Streptomyces peucetius bacterium, received approval for clinical use in the USA in 1974. Doxorubicin is available in different forms including pegylated and in liposomes versions. Doxorubicin is a key drug in the treatment of breast malignancy, Kaposi Sarcoma and several other diseases. Growth in the global market is set to be driven by rising incidence of cancer, development of technologically advanced systems for drug delivery, increasing awareness levels among patients and rising disposable incomes of people. Doxorubicin use is anticipated to increase significantly for ovarian cancer treatment and treatment of AIDS-related Kaposi`s sarcoma following failure of systemic chemotherapy done previously. Increasing number of hepatocellular carcinoma and growing survival rates also constitutes a major growth driver.

Amid the COVID-19 crisis, the global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2026, growing at a CAGR of 5.3% over the analysis period. Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period. This segment currently accounts for a 16.5% share of the global Doxorubicin market. Breast cancer represents a major category due to the constantly rising prevalence of breast cancer. Myocet, a non-pegylated liposomal doxorubicin, is approved in Canada and the European Union to treat metastatic breast cancer in combination with cyclophosphamide. Increasing incidence of lung cancer and rising awareness about available therapies is fueling demand for doxorubicin.

The U.S. Market is Estimated at $421.1 Million in 2021, While China is Forecast to Reach $106.6 Million by 2026

The Doxorubicin market in the U.S. is estimated at US$421.1 Million in the year 2021. The country currently accounts for a 40.56% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$106.6 Million in the year 2026 trailing a CAGR of 7.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the end of the analysis period. The US represents the largest regional market owing to the presence of a high number of people with different malignant tumors including lung, prostate, bladder, colon, breast and other malignancies. Use of the drug is high in the region, in mono as well as combination chemotherapies. The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major market for cancer therapies. Asia-Pacific represents another key market, due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region.

Ovarian Cancer Segment to Reach $179.7 Million by 2026

Liposomal delivery systems have considerably improved the safety and efficacy of chemotherapeutic agents, in comparison to non-liposomal formulations. The increasing prevalence of ovarian cancer spurs growing use of various forms of liposomal doxorubicin such as Caelyx/Doxil. In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$122.9 Million in the year 2020 will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.8 Million by the year 2026, while Latin America will expand at a 4.2% CAGR through the analysis period.

SELECT PLAYERS

Accord Healthcare Ireland Ltd; Cadila Healthcare Limited; Changzhou Kinyond Pharmaceutical Co., Ltd; Cipla, Limited; Hikma Thymoorgan Pharmazie GmbH; Janssen-Cilag Pty Limited; Meiji Seika Pharma Co., Ltd.; MicroBiopharm Japan Co., Ltd.; Novartis International AG; Pfizer, Inc.; Reddy’s Laboratories Ltd.; Synbias Pharma AG; Teva Pharmaceutical Industries Ltd; TTY Biopharm Company Limited

SEGMENTS

» Application (Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma, Other Applications)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Cancer - An Insight
Cancer Treatment
Chemotherapy: An Overview
An Introduction to Doxorubicin
Impact of Covid-19 and a Looming Global Recession
EXHIBIT 8: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
COVID-19 Impact on Global Doxorubicin Market
GLOBAL MARKET OVERVIEW
Global Doxorubicin Market Set to Witness Rapid Growth
US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
Breast Cancer Constitutes the Largest Application for Doxorubicin
Competition
New Entrants Seek Opportunities
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Cancer Incidence to Drive Market Growth
EXHIBIT: Breakdown of Total Number of Cancer Cases by Region: 2020
EXHIBIT: Breakdown of Total Number of Cancer Cases by Type: 2020
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Liposomal Delivery Systems Offer Significant Benefits
A Review of Liposomal-Doxorubicin Preparations
DOX Hydrochloride
Ageing Demographics to Drive Demand
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Market to Gain from Rise in Number of Breast Cancer Cases
Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results: As of Dec 30, 2019
Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
Age-Standardized Lung Cancer Rates for Select Countries
Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
Uptrend in Healthcare Spending Drives the Doxorubicin Demand
EXHIBIT 2: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Cancer Research Spending Continues to Witness Growth
Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
A Netherland’s Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
Combination Therapy: A Double Whammy Success
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
MARKET ANALYSIS
Rising Cancer Cases Spur Growth in Doxorubicin Market
EXHIBIT: Estimated Number of New Cancer Cases and Deaths in the US (2019)
TABLE: Number of FDA-Approved Oncology Drugs in the US (2010-2018)
EXHIBIT: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
TABLE: Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
Personalized Medicine Gathers Momentum for Cancer Treatment in the US
USA Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
CANADA
EXHIBIT: Number of New Cancer Cases in Canada: 2019
Canada Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
CHINA
EXHIBIT: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
China Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
EUROPE
MARKET ANALYSIS
Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
EXHIBIT: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
EXHIBIT: Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
Europe Current & Future Analysis for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Doxorubicin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
MARKET ANALYSIS
An Insight into Asia-Pacific Market for Doxorubicin
EXHIBIT: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
Asia-Pacific Current & Future Analysis for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Doxorubicin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
INDIA
India Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Doxorubicin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Doxorubicin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Doxorubicin by Application - Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Doxorubicin by Application - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma and Other Applications for the Years 2012, 2020 & 2027
Total Companies Profiled: 59

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com